Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

NCT05809336 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT05809336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05809336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 2/3
Overall status
Completed
Start date
May 1, 2019
Completion date
October 31, 2022
Enrollment
172 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor